☆ 4.7 Editorial Material

Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial

JOURNAL OF NUCLEAR MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy

Jeremie Calais et al.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Oncology

Nuclear medicine theranostics comes of age

Ken Herrmann et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy

Sandy Srinivas et al.

JOURNAL OF NUCLEAR MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor et al.

Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas

Sally F. Barrington et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)

添加到收藏夹

Article Medicine, General & Internal

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

C. Parker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.